AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24527718 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 77
Study 24528219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tositumomab and iodine(131)-tositumomab (TST/I(131)-TST)
Number of subjects: 93
Study 24528505 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Dialysis Virtual Ward (HDVW) intervention with weekly clinician-led telephone interviews for 2 weeks until VW discharge.
Number of subjects: 0
Study 24528505 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Dialysis Virtual Ward (HDVW) intervention.
Number of subjects: 0
Study 24528505 — intervention group
Group type: COMPARATOR
Intervention: Home Dialysis Virtual Ward (HDVW) re-hospitalization rate.
Number of subjects: 0
Study 24528907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 24528907 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24529158 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES)
Number of subjects: 610
Study 24529163 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus methotrexate (MTX) for 14 weeks
Number of subjects: 662
Study 24529291 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ramipril), specific dosage and duration not mentioned.
Number of subjects: 0
Study 24529291 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from clinical trial experts, ethics committee, public funding, medical society, and university sponsorship.
Number of subjects: 0
Study 24529936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stent strategy in non-LM bifurcation group
Number of subjects: 2897
Study 24529936 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stent strategy in LM bifurcation group
Number of subjects: 2897
Study 24530759 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG induction
Number of subjects: 84
Study 24530775 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity measured in counts/minute using accelerometer (Actigraph GT3X) worn for seven days
Number of subjects: 1365
Study 24530971 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative (131)I-tositumomab with fludarabine and ASCT
Number of subjects: 36
Study 24530971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (up to 210 mg/m2)
Number of subjects: 36
Study 24530971 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative (131)I-tositumomab
Number of subjects: 36
Study 24531331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk SIHD (n=1,066)
Number of subjects: 4204
Study 24531331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk SIHD (n=531)
Number of subjects: 4204
Study 24531550 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study 24531685 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated pulse contour analysis (UPCA)
Number of subjects: 20
Study 24531685 — intervention group
Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (TPTD)
Number of subjects: 20
Study 24532680 — intervention group
Group type: EXPERIMENTAL
Intervention: (68)Ga-PRGD2 PET/CT
Number of subjects: 20
Study 24532680 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG PET/CT
Number of subjects: 20
Study 24532785 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (Tysabri)
Number of subjects: 4821
Study 24532956 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosribbon(®)
Number of subjects: 16
Study 24533707 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT SNPs (rs6269, rs4633, rs4818, rs4680)
Number of subjects: 149
Study 24533707 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT SNPs (rs6269, rs4633, rs4680)
Number of subjects: 149
Study 24533707 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype 2 (GCGG)
Number of subjects: 149
Study 24534108 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (75 mg/m² for 5 to 7 days every 4 weeks until a suitable donor was found)
Number of subjects: 25
Study 24534108 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT after myeloablative pharmacokinetically targeted i.v. busulfan and fludarabine conditioning regimen
Number of subjects: 25
Study 24534109 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensitive patients according to CT criteria
Number of subjects: 88
Study 24534109 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET-positive patients (Deauville 4 to 5, n = 24)
Number of subjects: 88
Study 24534109 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET-negative patients (Deauville 1 to 3, n = 34)
Number of subjects: 88
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic ovary syndrome (PCOS)
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolactinemia
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature ovarian failure
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total testosterone level and free androgen index
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione and dehydroepiandrosterone sulfate (DHEAS)
Number of subjects: 573
Study 24534286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low age of menarche, high levels of high-sensitivity C-reactive protein and liver enzymes, low levels of sex hormone-binding globulin
Number of subjects: 573
Study 24535278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc plus raltegravir
Number of subjects: 44
Study 24535655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects
Number of subjects: 143
Study 24548045 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 137
Study 24548045 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline parent-youth verbal conflict
Number of subjects: 137
Study 24548045 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-youth verbal conflict at 6 months
Number of subjects: 137
Study 24548045 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-youth verbal conflict at 12 months
Number of subjects: 137
Study 24548045 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-youth conflict
Number of subjects: 137
Study 24548643 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml white wine (25 g alcohol) daily for 6 weeks
Number of subjects: 84
Study 24548643 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 ml beer (26 g alcohol) daily for 3 weeks
Number of subjects: 84
Study 24548643 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml vodka (30 g alcohol) daily for 4 weeks
Number of subjects: 84
Study 24548643 — intervention group
Group type: COMPARATOR
Intervention: white grape juice daily for 6 weeks
Number of subjects: 84
Study 24548643 — intervention group
Group type: COMPARATOR
Intervention: alcohol-free beer daily for 3 weeks
Number of subjects: 84
Study 24548643 — intervention group
Group type: COMPARATOR
Intervention: only orange juice daily for 4 weeks
Number of subjects: 84
Study 24549158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking of a current close friend
Number of subjects: 2586
Study 24549158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking of a close friend during schooldays
Number of subjects: 2586
Study 24549158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking behaviour of mothers and siblings (for men)
Number of subjects: 2586
Study 24549158 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking behaviour of mothers and siblings (for women)
Number of subjects: 2586
Study 24550219 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Number of subjects: 61
Study 24550219 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive insulin therapy (IIT)
Number of subjects: 61
Study 24550219 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with an increase in ISSI-2 ≥25%
Number of subjects: 61
Study 24552242 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 2164
Study 24552750 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher biomarker-calibrated protein intake (15% of energy intake)
Number of subjects: 144580
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sugars
Number of subjects: 353751
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fructose
Number of subjects: 353751
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Added fructose
Number of subjects: 353751
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugars
Number of subjects: 353751
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 353751
Study 24552754 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sucrose
Number of subjects: 353751
Study 24554062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib (dose escalation cohort 1: 200 mg twice daily, cohort 2: 200/400 mg daily) plus preoperative conformal radiotherapy (50 Gy in 25 fractions)
Number of subjects: 8
Study 24554062 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib plus RT
Number of subjects: 8
Study 24555130 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel semiautomated grading system (RetmarkerAMD)
Number of subjects: 89
Study 24555562 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with COPD
Number of subjects: 430
Study 24555562 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sputum in women
Number of subjects: 430
Study 24555562 — intervention group
Group type: COMPARATOR
Intervention: Men with COPD
Number of subjects: 430
Study 24555723 — intervention group
Group type: EXPERIMENTAL
Intervention: BK0023
Number of subjects: 0
Study 24555723 — intervention group
Group type: COMPARATOR
Intervention: Neupogen®
Number of subjects: 0
Study 24557359 — intervention group
Group type: EXPERIMENTAL
Intervention: Midstromal implant of an isolated Bowman layer graft
Number of subjects: 9
Study 24557701 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAN-100-positive patients
Number of subjects: 202
Study 24557701 — intervention group
Group type: COMPARATOR
Intervention: SPAN-100-negative patients
Number of subjects: 202
Study 24557701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 202
Study 24557701 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAN-100-positive status
Number of subjects: 202
Study 24558033 — intervention group
Group type: COMPARATOR
Intervention: Low dose naltrexone (4.5 mg/day) for 12 weeks in adults
Number of subjects: 46
Study 24558033 — intervention group
Group type: COMPARATOR
Intervention: Low dose naltrexone (0.1 mg/kg, maximum 4.5 mg/day) for 8 weeks in children
Number of subjects: 46
Study 24558033 — intervention group
Group type: COMPARATOR
Intervention: Low dose naltrexone and placebo
Number of subjects: 46
Study 24558173 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant obstructive sleep apnoea (OSA) defined as an apnoea/hypopnoea index ≥ 20 events·h(-1)
Number of subjects: 84
Study 24558173 — intervention group
Group type: COMPARATOR
Intervention: No significant obstructive sleep apnoea (OSA)
Number of subjects: 84
Study 24558979 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive samples from women with ICC
Number of subjects: 114
Study 24558979 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types detected in ICC cases
Number of subjects: 114
Study 24558979 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological diagnosis of cervical samples
Number of subjects: 114
Study 24558979 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of cervical cancer diagnosed
Number of subjects: 114
Study 24558979 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-infection recorded
Number of subjects: 114
Study 24559067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobenzym (hydrolytic enzymes: bromelain, trypsin; flavonoid: rutoside)
Number of subjects: 160
Study 24559067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24559258 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 64
Study 24559321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin followed by oral azole therapy (fluconazole or voriconazole) after 5 days if criteria met
Number of subjects: 250
Study 24559321 — intervention group
Group type: EXPERIMENTAL
Intervention: Early switch to oral azole therapy (≤ 7 days' anidulafungin)
Number of subjects: 250
Study 24559321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin followed by oral azole therapy
Number of subjects: 250
Study 24559465 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]·[IGFBP7] greater than 0.3 (ng/ml)(2)/1,000
Number of subjects: 420
Study 24559465 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]·[IGFBP7]
Number of subjects: 420
Study 24559784 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 51
Study 24559784 — intervention group
Group type: COMPARATOR
Intervention: ERCP tissue sampling
Number of subjects: 51
Study 24559803 — intervention group
Group type: COMPARATOR
Intervention: (18)F-fluorodeoxyglucose (18F-FDG) PET/CT
Number of subjects: 22
Study 24559803 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted MRI
Number of subjects: 22
Study 24559803 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both imaging modalities
Number of subjects: 22
Study 24559843 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical activity (measured by pedometer records)
Number of subjects: 9306
Study 24559843 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet behavior (self-reported on a 6-item survey)
Number of subjects: 9306
Study 24560330 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5mg for up to 12 weeks
Number of subjects: 24
Study 24561125 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 2792
Study 24561125 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 2792
Study 24561125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2792
Study 24561125 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 2792
Study 24561125 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 2792
Study 24561146 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of normal LV function and size after treatment
Number of subjects: 868
Study 24561146 — intervention group
Group type: EXPERIMENTAL
Intervention: Death or heart transplantation
Number of subjects: 868
Study 24561146 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently abnormal echocardiograms
Number of subjects: 868
Study 24561146 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of normalization
Number of subjects: 868
Study 24561146 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplantation or death after normalization
Number of subjects: 868
Study 24562448 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with docetaxel (40 mg/m²), cisplatin (40 mg/m²), and panitumumab (6 mg/kg) with radiation therapy (5040 cGy, 180 cGy/day × 28 days) starting week 5.
Number of subjects: 70
Study 24562448 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and panitumumab.
Number of subjects: 70
Study 24562641 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT during radiotherapy (mean dose 43 Gy)
Number of subjects: 52
Study 24563078 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion topotecan (0.4 mg/m² per day for 9-10 days every 3 weeks) with erlotinib (150 mg orally on days 1-10 of each cycle)
Number of subjects: 6
Study 24563078 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-infusion topotecan with erlotinib
Number of subjects: 6
Study 24563419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous cardiovascular disease risk reduction program
Number of subjects: 63
Study 24563419 — intervention group
Group type: COMPARATOR
Intervention: Prescription medications
Number of subjects: 63
Study 24563419 — intervention group
Group type: COMPARATOR
Intervention: Controls (matched participants)
Number of subjects: 63
Study 24563480 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183 (4.0 mg/m(2) recommended dose)
Number of subjects: 31
Study 24563480 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183 (7.0 mg flat dose)
Number of subjects: 31
Study 24563480 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183 (recommended dose)
Number of subjects: 31
Study 24563480 — intervention group
Group type: EXPERIMENTAL
Intervention: PM01183 (at or above recommended dose)
Number of subjects: 31
Study 24563690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM) of various durations (24-hour, 7-day, 14-day, 30-day)
Number of subjects: 647
Study 24563690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rhythm monitoring (IRM) of shorter duration (24-hour)
Number of subjects: 647
Study 24563781 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment for 12 weeks
Number of subjects: 30
Study 24564178 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in patients without diabetes mellitus who are not receiving statin therapy
Number of subjects: 0
Study 24564178 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in the overall population
Number of subjects: 0
Study 24564178 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in women and those at higher cardiovascular risk
Number of subjects: 0
Study 24564178 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels in patients with metabolic syndrome markers
Number of subjects: 0
Study 24564281 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in stable CF patients
Number of subjects: 50
Study 24564281 — intervention group
Group type: COMPARATOR
Intervention: MRI in non-CF control subjects
Number of subjects: 50
Study 24564281 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in CF patients with exacerbations before treatment
Number of subjects: 50
Study 24564281 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in CF patients with exacerbations after antibiotic therapy
Number of subjects: 50
Study 24565221 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg BID plus metformin
Number of subjects: 160
Study 24565221 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 160
Study 24566706 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962 10 mg/Kg intravenously fortnightly until disease progression or unacceptable toxicity
Number of subjects: 14
Study 24566706 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03446962
Number of subjects: 14
Study 24566733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily for 2 and 4 weeks
Number of subjects: 18
Study 24567125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric dietary pattern for 8 weeks
Number of subjects: 96
Study 24567125 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline irisin levels above the median
Number of subjects: 96
Study 24567804 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking
Number of subjects: 797
Study 24567843 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (lot A)
Number of subjects: 1016
Study 24567843 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-DT
Number of subjects: 1016
Study 24568177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 40-160 mg/day
Number of subjects: 114
Study 24568613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in healthy nonsmokers
Number of subjects: 30
Study 24568613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in mild smokers
Number of subjects: 30
Study 24568613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled LPS (20,000 endotoxin units) in both groups
Number of subjects: 30
Study 24569099 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily perphenazine dosing
Number of subjects: 257
Study 24569099 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily perphenazine dosing
Number of subjects: 257
Study 24569424 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar fasciectomy
Number of subjects: 26
Study 24569817 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of hemoglobin A1c (HbA1c)
Number of subjects: 512
Study 24569817 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 512
Study 24569817 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 512
Study 24569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collateral flow (collateral score 3-4)
Number of subjects: 60
Study 24569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor collateral flow (collateral score 0-2)
Number of subjects: 60
Study 24569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor collaterals who reperfused (TICI 2B-3)
Number of subjects: 60
Study 24569816 — intervention group
Group type: COMPARATOR
Intervention: Poor collaterals versus good collaterals
Number of subjects: 60
Study 24569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor reperfusion (TICI 0-2a) with poor collaterals
Number of subjects: 60
Study 24570910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower energy nutritional supply (42 kJ/kg/d) in experimental group
Number of subjects: 95
Study 24570910 — intervention group
Group type: COMPARATOR
Intervention: Routine permissive underfeeding nutritional supply (75 kJ/kg/d) in control group
Number of subjects: 95
Study 24571550 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto Intervention (EHR-embedded program for mailing FIT kits)
Number of subjects: 206
Study 24571550 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto Plus Intervention (mailed FIT kit plus tailored interventions)
Number of subjects: 206
Study 24571550 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (passive control)
Number of subjects: 206